Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes o...
Main Authors: | Jieun Kang, Jin Woo Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-97396-z |
Similar Items
-
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2021-07-01) -
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01) -
Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
by: Yuji Iwanami, et al.
Published: (2022-09-01) -
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01) -
Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
by: Benjamin Seeliger, et al.
Published: (2022-08-01)